DC Field | Value | Language |
---|---|---|
dc.contributor.author | Y Her | - |
dc.contributor.author | Y C Lee | - |
dc.contributor.author | J H Oh | - |
dc.contributor.author | Y E Choi | - |
dc.contributor.author | Chang Woo Lee | - |
dc.contributor.author | J S Kim | - |
dc.contributor.author | H M Kim | - |
dc.contributor.author | J W Yang | - |
dc.date.accessioned | 2017-04-19T09:33:18Z | - |
dc.date.available | 2017-04-19T09:33:18Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1226-8372 | - |
dc.identifier.uri | 10.1007/s12257-011-0678-2 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/10893 | - |
dc.description.abstract | Over the past several decades, the pharmacological effects of ginsenosides in Panax ginseng roots have been extensively investigated. Here, we developed a method for producing specific ginsenosides (F1 and F2) with good yields (F1:162 mg/g, F2:305 mg/g) using β-glycosidase purified from Aspergillus niger. In addition, each ginsenoside (at least 25 species) was separated and purified by high performance liquid chromatography (HPLC) using five different types of solvents and different purification steps. In addition, the Rg3:Rh2 mixture (1:1, w/w) was shown to inhibit a specific lung cancer cell line (NCI-H232) in vivo, displaying an anticancer effect at a dose lower than achieved using treatments with single Rg3 or Rh2. This finding suggests that the combination of ginsenosides for targeting anticancer is more effective than the use of a single ginsenoside from ginseng or red ginseng. | - |
dc.publisher | Springer | - |
dc.title | An application of β-glycosidase to transformation of ginsenosides for the effective production of specific ginsenosides with biological efficacy | - |
dc.title.alternative | An application of β-glycosidase to transformation of ginsenosides for the effective production of specific ginsenosides with biological efficacy | - |
dc.type | Article | - |
dc.citation.title | Biotechnology and Bioprocess Engineering | - |
dc.citation.number | 3 | - |
dc.citation.endPage | 546 | - |
dc.citation.startPage | 538 | - |
dc.citation.volume | 17 | - |
dc.contributor.affiliatedAuthor | Chang Woo Lee | - |
dc.contributor.alternativeName | 허율 | - |
dc.contributor.alternativeName | 이영철 | - |
dc.contributor.alternativeName | 오진환 | - |
dc.contributor.alternativeName | 최윤이 | - |
dc.contributor.alternativeName | 이창우 | - |
dc.contributor.alternativeName | 김진석 | - |
dc.contributor.alternativeName | 김환묵 | - |
dc.contributor.alternativeName | 양지원 | - |
dc.identifier.bibliographicCitation | Biotechnology and Bioprocess Engineering, vol. 17, no. 3, pp. 538-546 | - |
dc.identifier.doi | 10.1007/s12257-011-0678-2 | - |
dc.subject.keyword | Enzymatic process | - |
dc.subject.keyword | Ginsenoside combination | - |
dc.subject.keyword | Ginsenosides | - |
dc.subject.keyword | Lung cancer cell line (NCI-H23) | - |
dc.subject.keyword | Purification | - |
dc.subject.keyword | Solvent system | - |
dc.subject.local | enzymatic process | - |
dc.subject.local | Enzymatic process | - |
dc.subject.local | Ginsenoside combination | - |
dc.subject.local | ginsenoside | - |
dc.subject.local | Ginsenoside | - |
dc.subject.local | Ginsenosides | - |
dc.subject.local | Lung cancer cell line (NCI-H23) | - |
dc.subject.local | Purification | - |
dc.subject.local | purification | - |
dc.subject.local | Purifcation | - |
dc.subject.local | Solvent system | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.